Brainstorm Cell Therapeutics, Inc. (BCLI)
0.9302
-0.07
(-6.98%)
USD |
OTCM |
Oct 02, 16:00
Brainstorm Cell Therapeutics Enterprise Value : 11.62M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 11.62M |
| October 01, 2026 | 12.39M |
| September 30, 2026 | 11.84M |
| September 29, 2026 | 11.50M |
| September 28, 2026 | 11.68M |
| September 25, 2026 | 12.06M |
| September 24, 2026 | 11.83M |
| September 23, 2026 | 10.95M |
| September 22, 2026 | 11.76M |
| September 21, 2026 | 10.95M |
| September 18, 2026 | 11.28M |
| September 17, 2026 | 12.17M |
| September 16, 2026 | 12.16M |
| September 15, 2026 | 12.83M |
| September 14, 2026 | 13.08M |
| September 11, 2026 | 13.27M |
| September 10, 2026 | 12.72M |
| September 09, 2026 | 12.39M |
| September 08, 2026 | 12.28M |
| September 04, 2026 | 12.94M |
| September 03, 2026 | 13.16M |
| September 02, 2026 | 15.15M |
| September 01, 2026 | 14.24M |
| August 31, 2026 | 13.10M |
| August 28, 2026 | 13.75M |
| Date | Value |
|---|---|
| August 27, 2026 | 14.18M |
| August 26, 2026 | 14.59M |
| August 25, 2026 | 12.39M |
| August 24, 2026 | 12.39M |
| August 21, 2026 | 12.17M |
| August 20, 2026 | 13.05M |
| August 19, 2026 | 14.79M |
| August 18, 2026 | 16.91M |
| August 17, 2026 | 13.33M |
| August 14, 2026 | 12.28M |
| August 13, 2026 | 10.36M |
| August 12, 2026 | 10.92M |
| August 11, 2026 | 10.73M |
| August 10, 2026 | 10.07M |
| August 07, 2026 | 10.04M |
| August 06, 2026 | 10.18M |
| August 05, 2026 | 9.914M |
| August 04, 2026 | 9.876M |
| August 03, 2026 | 10.07M |
| July 31, 2026 | 11.28M |
| July 30, 2026 | 11.48M |
| July 29, 2026 | 11.23M |
| July 28, 2026 | 11.50M |
| July 27, 2026 | 11.66M |
| July 24, 2026 | 11.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Summit Therapeutics, Inc. | 12.62B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 19.78M |
| Clene, Inc. | 64.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.855M |
| Total Expenses (Quarterly) | 3.855M |
| EPS Diluted (Quarterly) | -0.3494 |
| Earnings Yield | -102.6% |
| Normalized Earnings Yield | -102.56 |